Compass says depression drug has long-lasting benefits
Compass Pathways reports six-month Phase 3 trial data showing rapid and durable benefits for its psilocybin-based depression treatment.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Compass Pathways has released six-month data from its second Phase 3 trial, known as COMP006. The results indicate a rapid and durable profile for the company's depression drug. Following the announcement, shares of Compass Pathways saw gains.
Coverage from STAT, Endpoints News, and Business Wire emphasizes the long-lasting benefits and durability of the drug's effects. Psychedelic Alpha and Moomoo report that this late-stage data supports the company's progress toward a regulatory filing. Compass Pathways intends to file for the drug by the end of the year.
According to Psychedelic Alpha, the company is targeting a launch in the first half of 2027.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 54m ago.
Quick answers
What specific trial data was released?
Compass Pathways announced six-month data from its second Phase 3 trial, referred to as COMP006.
What is the nature of the depression drug?
According to Endpoints News, the drug is a psilocybin-based treatment.
When is the drug expected to launch?
Coverage from Psychedelic Alpha indicates the company eyes a launch in the first half of 2027.
Coverage (5)
- Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile Business Wire · 10h ago
- Compass Pathways Shares Gain on Positive Late-Stage Trial Data for Depression Treatment Moomoo · 10h ago
- Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch Psychedelic Alpha · 10h ago
- Updated: Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing Endpoints News · 10h ago
- Compass says depression drug has long-lasting benefits STAT · 10h ago
Topics
Related trends
An 80-year-old woman with advanced Alzheimer's regained speech and mobility after taking psilocybin
An 80-year-old woman with Alzheimer's has regained speech and mobility after taking psilocybin.
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer's Phase 3 trial for the lung cancer drug Sigvotatug Vedotin failed to meet its primary endpoint for survival.
Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says
Definium Therapeutics' LSD-based depression treatment shows promising results in a pivotal trial, driving stock surge
We Are Admittedly a Bit Startled by This Medical Case Report About Giving an Elderly Woman With Advanced Alzheimer's a Gigantic Dose of Psychedelic Mushrooms Just to See What Would Happen
A controversial case report on psilocybin's effects on an Alzheimer's patient has sparked global interest.